164 related articles for article (PubMed ID: 15928093)
1. Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo.
Jendreyko N; Popkov M; Rader C; Barbas CF
Proc Natl Acad Sci U S A; 2005 Jun; 102(23):8293-8. PubMed ID: 15928093
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous, phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody enhances antiangiogenic effects in vivo.
Jendreyko N; Rader C; Barbas CF; Gaedicke G
Klin Padiatr; 2006; 218(3):143-51. PubMed ID: 16688670
[TBL] [Abstract][Full Text] [Related]
3. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway.
Siemeister G; Schirner M; Weindel K; Reusch P; Menrad A; Marmé D; Martiny-Baron G
Cancer Res; 1999 Jul; 59(13):3185-91. PubMed ID: 10397264
[TBL] [Abstract][Full Text] [Related]
4. Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors.
Jendreyko N; Popkov M; Beerli RR; Chung J; McGavern DB; Rader C; Barbas CF
J Biol Chem; 2003 Nov; 278(48):47812-9. PubMed ID: 12947084
[TBL] [Abstract][Full Text] [Related]
5. Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody.
Popkov M; Jendreyko N; McGavern DB; Rader C; Barbas CF
Cancer Res; 2005 Feb; 65(3):972-81. PubMed ID: 15705898
[TBL] [Abstract][Full Text] [Related]
6. [Tumor angiogenesis: new approaches to cancer therapy].
Marmé D
Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor activates the Tie family of receptor tyrosine kinases.
Singh H; Milner CS; Aguilar Hernandez MM; Patel N; Brindle NP
Cell Signal; 2009 Aug; 21(8):1346-50. PubMed ID: 19376222
[TBL] [Abstract][Full Text] [Related]
8. The temporal-spatial expression of VEGF, angiopoietins-1 and 2, and Tie-2 during tumor angiogenesis and their functional correlation with tumor neovascular architecture.
Tse V; Xu L; Yung YC; Santarelli JG; Juan D; Fabel K; Silverberg G; Harsh G
Neurol Res; 2003 Oct; 25(7):729-38. PubMed ID: 14579791
[TBL] [Abstract][Full Text] [Related]
9. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
[TBL] [Abstract][Full Text] [Related]
10. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis.
Trikha M; Zhou Z; Timar J; Raso E; Kennel M; Emmell E; Nakada MT
Cancer Res; 2002 May; 62(10):2824-33. PubMed ID: 12019160
[TBL] [Abstract][Full Text] [Related]
11. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
12. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
13. Angiopoietins in angiogenesis.
Fagiani E; Christofori G
Cancer Lett; 2013 Jan; 328(1):18-26. PubMed ID: 22922303
[TBL] [Abstract][Full Text] [Related]
14. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
15. Responses of vascular endothelial cells to angiogenic signaling are important for tumor cell survival.
Shan S; Robson ND; Cao Y; Qiao T; Li CY; Kontos CD; Garcia-Blanco M; Dewhirst MW
FASEB J; 2004 Feb; 18(2):326-8. PubMed ID: 14688196
[TBL] [Abstract][Full Text] [Related]
16. Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature.
Frischer JS; Huang J; Serur A; Kadenhe-Chiweshe A; McCrudden KW; O'Toole K; Holash J; Yancopoulos GD; Yamashiro DJ; Kandel JJ
Int J Oncol; 2004 Sep; 25(3):549-53. PubMed ID: 15289855
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
18. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
19. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
20. Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice.
Theurillat JP; Hainfellner J; Maddalena A; Weissenberger J; Aguzzi A
Am J Pathol; 1999 Feb; 154(2):581-90. PubMed ID: 10027415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
